MedTrace Logo

A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)

NCT04185415 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-12-01

No results posted yet for this study

Summary

The purpose of the study is to assess the safety and tolerability of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).

Conditions

Interventions

DRUG

bepranemab

bepranemab will be administered in a predefined dosage. * Pharmaceutical Form: Solution for infusion * Route of Administration: Intravenous

DRUG

Placebo

* Pharmaceutical Form: Solution for infusion * Concentration: 0.9% w/v sodium chloride aqueous solution * Route of Administration: Intravenous

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-03
Primary Completion
2021-11-17
Completion
2021-11-17

Countries

  • Belgium
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04185415 on ClinicalTrials.gov